SCHEMBL4148191

SCHEMBL4148191

CCN(CC)CCN(C)c1ccc(-c2nc3c(C(=O)Nc4cnccc4C)ccnc3[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 14/20 0.61
GSK3A P49840 5/20 0.50
RAD52 P43351 1/20 0.36
UHRF1 Q96T88 1/20 0.36
CHEK1 O14757 1/20 0.35
MAP4K4 O95819 1/20 0.35
LCK P06239 1/20 0.35
CSF1R P07333 1/20 0.35
PIM1 P11309 1/20 0.35
PHKG2 P15735 1/20 0.35
MARK3 P27448 1/20 0.35
KDR P35968 1/20 0.35
FLT3 P36888 1/20 0.35
CLK2 P49760 1/20 0.35
ITK Q08881 1/20 0.35
MAP4K2 Q12851 1/20 0.35
DYRK1A Q13627 1/20 0.35
MARK2 Q7KZI7 1/20 0.35
PIM3 Q86V86 1/20 0.35
MINK1 Q8N4C8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8237753 0.86 GSK3B (0.61) GSK3BGSK3AMAPT
SCHEMBL4167014 0.84 GSK3B (0.43) GSK3BGSK3ARAD52UHRF1CHEK1
SCHEMBL4152895 0.82 GSK3B (0.60) GSK3BGSK3ARAD52UHRF1MAPT
SCHEMBL4145731 0.82 GSK3B (0.57) GSK3BGSK3ARAD52UHRF1MAPT
SCHEMBL4152652 0.82 GSK3B (0.47) GSK3BGSK3ARAD52UHRF1IRAK4
SCHEMBL4148115 0.82 GSK3B (0.54) GSK3BGSK3ARAD52UHRF1
SCHEMBL4152121 0.81 GSK3B (0.53) GSK3BGSK3ARAD52UHRF1
SCHEMBL4161701 0.81 GSK3B (0.59) GSK3BGSK3APIM1AURKBMAPT
SCHEMBL4147509 0.81 GSK3B (0.59) GSK3BGSK3AMAPT
SCHEMBL4152889 0.80 GSK3B (0.52) GSK3BGSK3ARAD52UHRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885RAD52 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.